What’s Instore For Big Pharma In 2017?Rupert Hargreaves
What's Instore For Big Pharma In 2017?
The US pharmaceutical industry has had a tough 2016, and according to Morgan Stanley, the outlook for the sector is no better next year.
Indeed, according to a lengthy report on the state of the pharmaceutical industry from Morgan, there are few catalysts for the sector’s growth next year and thanks to this the industry will be at the mercy of political decisions.
- Valeant Pharmaceuticals Intl Inc Downgraded After Ackman Cuts Stake
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.